Pancreatic Cancer Research

ResearcherInsermActive in the last 2 years

Alain Sauvanet Sauvanet

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7436-5999; OpenAlex author ID A5067979346, A5110486994. Sources: OpenAlex.

Their work

Papers
55 (first author 5, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
183
Papers, trials and grants by year

2011: 1 paper · 2012: 3 papers · 2013: 2 papers · 2014: 3 papers · 2015: 7 papers · 2016: 1 paper · 2017: 1 paper · 2018: 4 papers · 2019: 5 papers · 2020: 1 paper · 2021: 2 papers · 2022: none · 2023: 2 papers · 2024: 7 papers · 2025: 10 papers · 2026: 6 papers

Papers 50 of 55

  1. The European Multidisciplinary Evidence-Based Guideline on Pancreatic Cancer: Methodological Protocol. Co-author DOI 10.1002/gin2.70074↗
  2. Laparoscopic left pancreatectomy is safe for the treatment of pancreatic ductal adenocarcinoma treated by chemoradiotherapy compared to open left pancreatectom… Co-author DOI 10.1007/s00464-026-12991-3↗
  3. Response to 'Towards an individualized strategy in perioperative chemotherapy for pancreatic cancer'. Co-author DOI 10.1038/s41416-025-03294-w↗
  4. Neoadjuvant Oxaliplatin and Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: CT Features of Chemotherapy-Associated Liver Injury and Postoperative… Co-author DOI 10.1245/s10434-026-19545-w↗
  5. ASO Visual Abstract: Neoadjuvant Oxaliplatin and Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: CT Features of Chemotherapy-Associated Liver Inj… Co-author DOI 10.1245/s10434-026-19641-x↗
  6. ASO Author Reflections: Neoadjuvant Oxaliplatin and Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: CT Features of Chemotherapy-Associated Liver … Co-author DOI 10.1245/s10434-026-19683-1↗
  7. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  8. The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study. Co-author DOI 10.1016/j.annonc.2024.12.015↗
  9. Distal pancreatectomy with celiac axis resection (DP-CAR) for pancreatic ductal adenocarcinoma in a retrospective monocentric cohort: neoadjuvant treatment and… Last author DOI 10.1016/j.hpb.2025.04.009↗
  10. Laparoscopic pancreatoduodenectomy is safe for the treatment of pancreatic ductal adenocarcinoma treated by chemoradiotherapy compared with open pancreatoduode… Co-author DOI 10.1016/j.surg.2024.09.041↗
  11. Laparoscopic compared with open pancreatoduodenectomy is safe for the treatment of pancreatic ductal adenocarcinoma treated by chemoradiotherapy. Last author DOI 10.1016/j.surg.2025.109281↗
  12. Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an interna… Co-author DOI 10.1038/s41416-025-03025-1↗
  13. Comparison of radiological and pathological tools to assess response to neoadjuvant treatment in resected pancreatic ductal adenocarcinoma patients. Co-author DOI 10.1177/17588359251403909↗
  14. Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PROD… Co-author DOI 10.1200/jco-24-01378↗
  15. Prognosis Associated with Complete Pathological Response Following Neoadjuvant Treatment for PancreaTic AdenOcarciNOma in the FOFLIRINOX Era: the Multicenter T… Co-author DOI 10.1245/s10434-024-16735-2↗
  16. Total Pancreatectomy for Locally Advanced Pancreatic Adenocarcinoma with Coeliac Trunk Resection and Retrograde Gastric Revascularization Through Aorto-Hepato-… Co-author DOI 10.1245/s10434-024-16844-y↗
  17. Pathological Complete Response in Patients With Resected Pancreatic Adenocarcinoma After Preoperative Chemotherapy. Co-author DOI 10.1001/jamanetworkopen.2024.17625↗
  18. [Hereditary and familial forms of pancreatic adenocarcinoma: Genetic determinism, patients eligible for systematic screening, screening methods and results]. Co-author DOI 10.1016/j.bulcan.2023.11.002↗
  19. Should liver metastases of pancreatic adenocarcinoma be resected? Co-author DOI 10.1016/j.jviscsurg.2023.12.006↗
  20. Splenic vein tumor thrombosis is a major prognostic factor in distal pancreatic adenocarcinoma. Co-author DOI 10.1016/j.surg.2023.10.028↗
  21. Influence of pancreatic fistula on survival after upfront pancreatoduodenectomy for pancreatic ductal adenocarcinoma: multicentre retrospective study. Co-author DOI 10.1093/bjsopen/zrae125↗
  22. Distal Pancreatectomy for Body Pancreatic Ductal Adenocarcinoma: Is Splenectomy Necessary? A Propensity Score Matched Study. Last author DOI 10.1245/s10434-024-15220-0↗
  23. ASO Author Reflections: Rethinking Spleen Preservation in Patients with Body Pancreatic Ductal Adenocarcinoma. First author DOI 10.1245/s10434-024-15273-1↗
  24. Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer: An International Multicenter Cohort Study. Co-author DOI 10.1245/s10434-022-12387-2↗
  25. Robot-Assisted Versus Laparoscopic Distal Pancreatectomy in Patients with Resectable Pancreatic Cancer: An International, Retrospective, Cohort Study. Co-author DOI 10.1245/s10434-022-13054-2↗
  26. Acute Pancreatitis as the Initial Presentation of Pancreatic Adenocarcinoma does not Impact Short- and Long-term Outcomes of Curative Intent Surgery: A Study o… Co-author DOI 10.1007/s00268-021-06205-1↗
  27. A Novel Pancreatic Fistula Risk Score Including Preoperative Radiation Therapy in Pancreatic Cancer Patients. Last author DOI 10.1007/s11605-020-04600-y↗
  28. Vascular Resection for Pancreatic Cancer: 2019 French Recommendations Based on a Literature Review From 2008 to 6-2019. First author DOI 10.3389/fonc.2020.00040↗
  29. Characteristic and outcomes of patients with pathologic complete response after preoperative treatment in borderline and locally advanced pancreatic adenocarci… Co-author DOI 10.1016/j.clinre.2019.03.007↗
  30. 18F-FDG PET/CT in pancreatic adenocarcinoma: A role at initial imaging staging? First author DOI 10.1016/j.diii.2019.07.006↗
  31. Risk and Predictors of Postoperative Morbidity and Mortality After Pancreaticoduodenectomy for Pancreatic Neuroendocrine Neoplasms: A Comparative Study With Pa… Co-author DOI 10.1097/mpa.0000000000001273↗
  32. Appropriateness of pancreatic resection in high-risk individuals for familial pancreatic ductal adenocarcinoma: a patient-level meta-analysis and proposition o… Co-author DOI 10.1177/2050640618824910↗
  33. How Does Chemoradiotherapy Following Induction FOLFIRINOX Improve the Results in Resected Borderline or Locally Advanced Pancreatic Adenocarcinoma? An AGEO-FRE… Co-author DOI 10.1245/s10434-018-6931-6↗
  34. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. Co-author DOI 10.1056/nejmoa1809775↗
  35. Outcomes After Distal Pancreatectomy with Celiac Axis Resection for Pancreatic Cancer: A Pan-European Retrospective Cohort Study. Co-author DOI 10.1245/s10434-018-6391-z↗
  36. Correction to: Outcomes After Distal Pancreatectomy with Celiac Axis Resection for Pancreatic Cancer: A Pan-European Retrospective Cohort Study. Co-author DOI 10.1245/s10434-018-6442-5↗
  37. In vitro, in vivo and ex vivo demonstration of the antitumoral role of hypocretin-1/orexin-A and almorexant in pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.24084↗
  38. Resectable invasive IPMN versus sporadic pancreatic adenocarcinoma of the head of the pancreas: Should these two different diseases receive the same treatment?… Co-author DOI 10.1016/j.ejso.2017.06.011↗
  39. Modified Appleby procedure for borderline resectable/locally advanced distal pancreatic adenocarcinoma: A major procedure for selected patients. Last author DOI 10.1016/j.jviscsurg.2015.11.014↗
  40. Severe Jaundice Increases Early Severe Morbidity and Decreases Long-Term Survival after Pancreaticoduodenectomy for Pancreatic Adenocarcinoma. Co-author DOI 10.1016/j.jamcollsurg.2015.03.058↗
  41. State of the art and future directions of pancreatic ductal adenocarcinoma therapy. Co-author DOI 10.1016/j.pharmthera.2015.08.006↗
  42. Laparoscopic Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma: Time for a Randomized Controlled Trial? Results of an All-inclusive National Observati… Co-author DOI 10.1097/sla.0000000000001479↗
  43. High c-Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis. Co-author DOI 10.1111/his.12691↗
  44. Sonic hedgehog and Gli1 expression predict outcome in resected pancreatic adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-14-0667↗
  45. Pancreatic adenocarcinoma with venous involvement: is up-front synchronous portal-superior mesenteric vein resection still justified? A survey of the Associati… Co-author DOI 10.1245/s10434-014-4304-3↗
  46. [Surgery for lesions at risk for pancreatic cancer]. Co-author PMID 26016199↗
  47. Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to… Co-author DOI 10.1016/j.ejca.2014.07.011↗
  48. Pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a French multicentre prospective evaluation of resection margins in 150 evaluable specimens. Co-author DOI 10.1111/hpb.12061↗
  49. EGFR expression in pancreatic adenocarcinoma. Relationship to tumour morphology and cell adhesion proteins. Co-author DOI 10.1136/jclinpath-2013-201662↗
  50. S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma. Co-author DOI 10.1016/j.ejca.2013.04.017↗

Closest collaborators

The 25 strongest of 183 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Safi Dokmak · 12 shared papers, 2015–2026 · strength 2.31
  2. Mickaël Lesurtel · 9 shared papers, 2018–2026 · strength 1.90
  3. Maxime Ronot · 5 shared papers, 2025–2026 · strength 1.31
  4. Vinciane Rebours · 7 shared papers, 2012–2025 · strength 1.13
  5. Tatiana Codjia · 4 shared papers, 2024–2026 · strength 1.04
  6. Jerome F. Cros · 9 shared papers, 2013–2025 · strength 0.99
  7. Louis de Mestier · 5 shared papers, 2015–2026 · strength 0.92
  8. Sébastien Gaujoux · 6 shared papers, 2019–2025 · strength 0.89
  9. Elias Karam · 3 shared papers, 2025–2026 · strength 0.89
  10. Jean‐Robert Delpéro · 11 shared papers, 2014–2021 · strength 0.88
  11. Farha Tessier · 3 shared papers, 2026 · strength 0.84
  12. Jules Grégory · 3 shared papers, 2026 · strength 0.84
  13. Jean‐Baptiste Bachet · 10 shared papers, 2012–2024 · strength 0.80
  14. Christian Hobeika · 2 shared papers, 2024 · strength 0.66
  15. António Sá Cunha · 6 shared papers, 2015–2024 · strength 0.61
  16. Olivia Hentic Dhome · 3 shared papers, 2019–2025 · strength 0.59
  17. Pascal R. Hammel · 13 shared papers, 2011–2019 · strength 0.57
  18. Ugo Marchèse · 3 shared papers, 2024–2025 · strength 0.54
  19. Olivıer Turrini · 6 shared papers, 2014–2024 · strength 0.52
  20. Anne Couvelard Benveniste · 8 shared papers, 2012–2025 · strength 0.51
  21. Philippe Bachellier · 6 shared papers, 2014–2025 · strength 0.48
  22. François Paye · 9 shared papers, 2012–2021 · strength 0.43
  23. Milena Muzzolini · 2 shared papers, 2024–2025 · strength 0.41
  24. Christophe Laurent · 3 shared papers, 2019–2025 · strength 0.41
  25. Renato Micelli Lupinacci · 2 shared papers, 2021–2024 · strength 0.39

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.